UTMDNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

UTAH MEDICAL PRODUCTS INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026

$74.55+0.04 (+0.05%)

Close on Oct 19, 2026

Market cap: $237.37M
P/E (TTM): 22.7
Dividend yield: –

UTAH MEDICAL PRODUCTS INC income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31
Revenue	39	41	50	52	49	42	47	42	41	39	40	41	40	42	38	25	26
Cost of Revenue	17	17	20	20	18	17	17	16	15	16	16	16	16	16	15	12	12
Gross Profit	22	24	30	32	31	26	29	26	26	24	24	25	24	25	22	13	14
Research & Development	0.67	0.81	0.56	0.49	0.53	0.49	0.48	0.45	0.45	0.48	0.52	0.46	0.49	0.56	-0.52	0.40	0.36
Selling, General & Admin	9.93	9.74	13	12	12	11	11	7.16	6.94	7.03	8.01	8.32	8.95	9.55	10	3.89	4.00
Selling & Marketing	2.05	1.90	1.69	1.51	1.41	1.55	1.74	1.71	1.54	1.67	2.16	2.21	2.79	2.71	-2.82	1.54	1.58
General & Administrative	7.88	7.84	11	10	10	9.80	9.61	5.45	5.39	5.36	5.85	6.11	6.16	6.84	-7.23	2.35	2.41
Operating Income	11	14	17	20	19	14	18	19	19	16	16	16	15	15	12	8.92	9.43
Interest Expense	–	–	–	–	–	–	–	–	–	–	0.07	0.29	0.44	0.65	0.86	0.03	0.05
Other Non-Operating Income	-0.12	-0.17	0.26	0.19	0	0	-0.01	0.44	-0.03	0.13	–	–	–	–	–	–	–
Asset Impairment Charges	–	–	0	0	0	0	0	0	0	–	–	–	–	–	–	–	–
Gain (Loss) on Investments	–	–	–	–	–	0	0	0.03	0	0	–	0	0	-0.18	0.01	0.04	0.21
Gain (Loss) on Sale of Assets	–	–	–	0	0	0.00	-0.02	0.41	-0.02	0.01	0.00	-0.04	-0.01	0	0	0	0.00
Pretax Income	14	17	20	21	19	14	18	19	19	16	16	16	14	15	11	9.04	9.58
Income Tax Expense	2.82	2.93	3.45	4.19	4.27	3.04	3.16	0.90	11	4.29	3.70	4.43	3.07	4.37	3.67	3.03	3.32
Net Income incl. Noncontrolling Interests	11	14	17	16	15	11	15	19	8.51	12	12	11	11	10	7.41	6.01	6.26
EPS (Basic)(per share)	3.48	3.96	4.58	4.53	4.05	2.95	3.96	4.97	2.29	3.23	3.16	3.04	3.06	2.77	2.04	1.66	1.73
EPS (Diluted)(per share)	3.48	3.96	4.57	4.52	4.04	2.94	3.94	4.95	2.28	3.22	3.14	3.02	3.02	2.74	2.03	1.65	1.72
Shares Outstanding (Basic, Weighted)(shares)	3.24	3.50	3.63	3.64	3.65	3.66	3.72	3.73	3.72	3.75	3.75	3.75	3.73	3.68	3.63	3.62	–
Shares Outstanding (Diluted, Weighted)(shares)	3.24	3.50	3.64	3.64	3.66	3.67	3.74	3.75	3.74	3.77	3.77	3.77	3.78	3.71	3.65	3.64	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 57.9%
Operating margin: 28.4%
Net margin: –
Return on equity, FY2025: –

Financial strength

Current ratio: 48.62
Debt to equity: 0.00
Debt to assets: 0.2%
Cash to current liabilities: 4228.4%

Valuation

P/E ratio: 22.7
Price to sales: 6.57
Price to book: 1.95
Dividend yield: –